News

Trikafta (elexacaftor/tezacaftor/ivacaftor) was seen to keep lung function from getting worse in people with cystic fibrosis (CF) for up to two years, a study found. These findings counter previous studies wherein the active ingredients in Trikafta, alone or in combinations of two, were seen to slow, but not…

The first patient has been dosed in a Phase 1b/2 clinical trial testing WRAIR-PAM-CF1, an investigational bacteriophage therapy, in adult cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa lung infections. The PHAGE trial (NCT05453578) is recruiting an estimated 72 such patients who tested positive for a P. aeruginosa infection…

The Cystic Fibrosis Foundation is investing up to $15 million in ReCode Therapeutics to support the development of the company’s inhaled mRNA-based therapy for cystic fibrosis (CF). “We are excited to expand our relationship with the CF Foundation with this investment in our CFTR mRNA program for cystic…

Renexxion is seeking clearance from the U.S. Food and Drug Administration (FDA) for clinical testing of the treatment candidate naronapride in people with cystic fibrosis (CF) and gastrointestinal (GI) problems. The Ireland-based biopharmaceutical company, which specializes in treatments for gastrointestinal disorders, announced the opening of an investigational new…

Sionna Therapeutics is forging ahead in the new year with its preclinical and clinical programs aimed at developing small molecules — such as SION-638 — as possible treatments for cystic fibrosis (CF). An ongoing Phase 1 trial, now enrolling participants, is testing SION-638 in healthy volunteers. Dosing…

A novel inhaled antibiotic that Spexis is developing to treat infections of Pseudomonas aeruginosa — the key bacterial agent of lung infections in cystic fibrosis (CF) — showed a good safety profile in a first trial conducted in healthy volunteers, the company announced. “The first clinical data with our inhaled…

Living closer to composting sites, where solid urban waste is collected and stored, may increase the risk of more severe disease for adults with cystic fibrosis (CF), according to a U.K. study. Close proximity to such sites was linked with worse lung function and more fungal infections among adults. The…

Despite widespread use of telehealth, fewer cystic fibrosis (CF) patients in the U.S. met the recommendations for routine follow-up during the COVID-19 pandemic in 2020 than in 2019. However, the use of telehealth was related to higher adherence to aspects of CF care that can be evaluated remotely. “In…

Physical activity increases fat-free mass — the lean mass in muscles, organs, bones, ligaments and tendons — in adolescents with cystic fibrosis (CF), according to a recent study. The findings also showed that fat-free mass was significantly lower in those with CF-related liver disease. The study, “…

Pseudomonas aeruginosa bacteria can become resistant to the antibiotic tobramycin by clumping into more and larger aggregates and making more of a protective sugar molecule called Psl, a study reported. It used samples of sputum from a small group of children with cystic fibrosis (CF) who received inhaled…